drugset / Trial / NCT07358585
A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a phase Ib/II study to evaluate the efficacy, safety and tolerance of HLX43 combined with HLX07 or Serplulimab in patients with advanced or metastatic colorectal cancer failed or intolerance to standard first-line therapy
Timeline
- Start
- 2026-01-31
- Primary completion
- 2027-07-28
- Completion
- 2028-08-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX43 | Other / unclassified | — | Intravenous |
| Subject | PIMURUTAMAB | Monoclonal antibody | 1000 mg | Intravenous |
| Subject | Serplulimab | Monoclonal antibody | 300 mg | Intravenous |